174 related articles for article (PubMed ID: 11798775)
41. [Influence of As(2)O(3) on proteasome beta(1)-subunit in NB4 cells].
Lü XH; Chen Y; Zhang M; He PC; Wang HY; Ni ZF; Lu R
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):579-82. PubMed ID: 19549367
[TBL] [Abstract][Full Text] [Related]
42. The expression of immediate early gene X-1 (IEX-1) is differentially induced by retinoic acids in NB4 and KG1 cells: possible implication in the distinct phenotype of retinoic acid-responsive and -resistant leukemic cells.
Arlt A; Minkenberg J; Kocs B; Grossmann M; Kruse ML; Fölsch UR; Schäfer H
Leukemia; 2004 Oct; 18(10):1646-55. PubMed ID: 15306824
[TBL] [Abstract][Full Text] [Related]
43. [Effects of arsenic trioxide on the subcellular localization of PML/PML-RARalpha protein in leukemic cells].
Ni J; Chen G; Zhu J; Zhong H; Tang W; Li X; Xiong S; Shen Z; Chen S; Wang Z; Chen L
Zhonghua Xue Ye Xue Za Zhi; 1997 Jan; 18(1):32-4. PubMed ID: 15622748
[TBL] [Abstract][Full Text] [Related]
44. Acute promyelocytic leukemia and variant fusion proteins: PLZF-RARα fusion protein at a glance.
Hussain L; Maimaitiyiming Y; Islam K; Naranmandura H
Semin Oncol; 2019 Apr; 46(2):133-144. PubMed ID: 31126665
[TBL] [Abstract][Full Text] [Related]
45. Targeting PML/RARalpha transcript with DNAzymes results in reduction of proliferation and induction of apoptosis in APL cells.
Kabuli M; Yin JA; Tobal K
Hematol J; 2004; 5(5):426-33. PubMed ID: 15448669
[TBL] [Abstract][Full Text] [Related]
46. Constitutive expression of the promyelocytic leukemia-associated oncogene PML-RARalpha in TF1 cells: isoform-specific and retinoic acid-dependent effects on growth, bcl-2 expression, and apoptosis.
Slack JL; Yu M
Blood; 1998 May; 91(9):3347-56. PubMed ID: 9558392
[TBL] [Abstract][Full Text] [Related]
47. Effects on differentiation by the promyelocytic leukemia PML/RARalpha protein depend on the fusion of the PML protein dimerization and RARalpha DNA binding domains.
Grignani F; Testa U; Rogaia D; Ferrucci PF; Samoggia P; Pinto A; Aldinucci D; Gelmetti V; Fagioli M; Alcalay M; Seeler J; Grignani F; Nicoletti I; Peschle C; Pelicci PG
EMBO J; 1996 Sep; 15(18):4949-58. PubMed ID: 8890168
[TBL] [Abstract][Full Text] [Related]
48. Effect of all-trans retinoic acid and arsenic trioxide on tissue factor expression in acute promyelocytic leukemia cells.
Guo W; Wang H; Zhao W; Zhu J; Ju B; Wang X
Chin Med J (Engl); 2001 Jan; 114(1):30-4. PubMed ID: 11779431
[TBL] [Abstract][Full Text] [Related]
49. Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid.
Kitamura K; Hoshi S; Koike M; Kiyoi H; Saito H; Naoe T
Br J Haematol; 2000 Mar; 108(4):696-702. PubMed ID: 10792271
[TBL] [Abstract][Full Text] [Related]
50. A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARalpha and T18 oncoproteins.
Zhong S; Delva L; Rachez C; Cenciarelli C; Gandini D; Zhang H; Kalantry S; Freedman LP; Pandolfi PP
Nat Genet; 1999 Nov; 23(3):287-95. PubMed ID: 10610177
[TBL] [Abstract][Full Text] [Related]
51. Histone deacetylases and transcriptional therapy with their inhibitors.
Pandolfi PP
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S17-9. PubMed ID: 11587360
[TBL] [Abstract][Full Text] [Related]
52. The clinically relevant CHK1 inhibitor MK-8776 induces the degradation of the oncogenic protein PML-RARα and overcomes ATRA resistance in acute promyelocytic leukemia cells.
Franza M; Albanesi J; Mancini B; Pennisi R; Leone S; Acconcia F; Bianchi F; di Masi A
Biochem Pharmacol; 2023 Aug; 214():115675. PubMed ID: 37406967
[TBL] [Abstract][Full Text] [Related]
53. Selenite promotes all-trans retinoic acid-induced maturation of acute promyelocytic leukemia cells.
Misra S; Selvam AK; Wallenberg M; Ambati A; Matolcsy A; Magalhaes I; Lauter G; Björnstedt M
Oncotarget; 2016 Nov; 7(46):74686-74700. PubMed ID: 27732960
[TBL] [Abstract][Full Text] [Related]
54. Activation of
Zhang F; Zhu YL; Deng WL; Zhu J; Zhang J
J Leukoc Biol; 2017 Mar; 101(3):655-664. PubMed ID: 27605212
[TBL] [Abstract][Full Text] [Related]
55. Constitutive degradation of PML/RARalpha through the proteasome pathway mediates retinoic acid resistance.
Fanelli M; Minucci S; Gelmetti V; Nervi C; Gambacorti-Passerini C; Pelicci PG
Blood; 1999 Mar; 93(5):1477-81. PubMed ID: 10029573
[TBL] [Abstract][Full Text] [Related]
56. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.
Zhang XW; Yan XJ; Zhou ZR; Yang FF; Wu ZY; Sun HB; Liang WX; Song AX; Lallemand-Breitenbach V; Jeanne M; Zhang QY; Yang HY; Huang QH; Zhou GB; Tong JH; Zhang Y; Wu JH; Hu HY; de Thé H; Chen SJ; Chen Z
Science; 2010 Apr; 328(5975):240-3. PubMed ID: 20378816
[TBL] [Abstract][Full Text] [Related]
57. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL.
He LZ; Guidez F; Tribioli C; Peruzzi D; Ruthardt M; Zelent A; Pandolfi PP
Nat Genet; 1998 Feb; 18(2):126-35. PubMed ID: 9462740
[TBL] [Abstract][Full Text] [Related]
58. Differential changes of retinoid-X-receptor (RXR alpha) and its RAR alpha and PML-RAR alpha partners induced by retinoic acid and cAMP distinguish maturation sensitive and resistant t(15;17) promyelocytic leukemia NB4 cells.
Duprez E; Lillehaug JR; Gaub MP; Lanotte M
Oncogene; 1996 Jun; 12(11):2443-50. PubMed ID: 8649786
[TBL] [Abstract][Full Text] [Related]
59. PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter.
Tabe Y; Konopleva M; Kondo Y; Contractor R; Jin L; Ruvolo V; Tsutsumi-Ishii Y; Miyake K; Miyake N; Ohsaka A; Nagaoka I; Issa JP; Andreeff M
Ann Hematol; 2006 Oct; 85(10):689-704. PubMed ID: 16832676
[TBL] [Abstract][Full Text] [Related]
60. Curing APL: differentiation or destruction?
Kogan SC
Cancer Cell; 2009 Jan; 15(1):7-8. PubMed ID: 19111876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
